Nevro Names Stryker Exec Greg Siller as Chief Commercial Officer

Nevro, a company delivering solutions to treat chronic pain, has appointed Greg Siller as senior vice president and chief commercial officer, effective June 19.
 
Siller replaces Niamh Pellegrini, who will be leaving Nevro on June 9. In conjunction will this appointment, Nevro also announced it’s updating revenue guidance for Q2 2023 from its previous range of $110-112 million to a range of $106-108 million. The company plans to update its annual guidance when it reports Q2 2023 financial results.
 
“I am delighted to welcome Greg to the Nevro team,” Kevin Thornal, CEO and president of Nevro told the press. “For the last 17 years, Greg has led the development, implementation and execution of successful commercial strategies and programs for several Stryker businesses, including most recently Stryker’s Interventional Spine business. His proven track record of success and his passion for building high performing commercial organizations will be instrumental as we continue to focus on accelerating revenue growth, developing underpenetrated markets such as painful diabetic neuropathy and non-surgical back pain, and launching new products, including our new HFX iQ system. I’m confident that Greg’s appointment will further bolster our ability to capitalize on the growth opportunities in front of us and accelerate our market performance. I also want to thank Niamh for her contributions over the last four years and wish her success in her future endeavors.”
 
Siller spent the last 17 years at Stryker, where he had several positions in sales and marketing. He was most recently vice president and general manager of the Stryker Interventional Spine business since January 2020. Prior to that, he was Stryker Surgical Technologies’ senior director of sales from January 2019 to December 2019. He was also part of the core team that successfully divided the Surgical division into two successful business units.
 
“I am thrilled to be joining Nevro, and I look forward to furthering its mission of delivering solutions that continue to set the standard for enduring patient outcomes in chronic pain treatment,” said Siller. “Nevro’s 10 kHz Therapy provides a unique and highly differentiated technology for patients and physicians in three large, underpenetrated markets. I look forward to bringing my commercial experience and passion for customers to ensure HFX becomes a standard of care in the treatment of chronic pain.”